These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 23316314)

  • 21. Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.
    Ambegaonkar BM; Bash LD; Chirovsky DR; Jameson K; Grant S; Nocea G; Pettersson B; Sazonov V
    Eur J Intern Med; 2013 Oct; 24(7):656-63. PubMed ID: 23953848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002.
    Keevil JG; Cullen MW; Gangnon R; McBride PE; Stein JH
    Circulation; 2007 Mar; 115(11):1363-70. PubMed ID: 17353444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy.
    Zhao W; Zheng XL; Jiang ZN; Liao XB; Zhao SP
    Int J Cardiol; 2017 Dec; 248():355-360. PubMed ID: 28689987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mixed dyslipidemias in primary care patients in France.
    Laforest L; Ambegaonkar BM; Souchet T; Sazonov V; Van Ganse E
    Vasc Health Risk Manag; 2012; 8():247-54. PubMed ID: 22566746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China.
    Lu Y; Zhang H; Lu J; Ding Q; Li X; Wang X; Sun D; Tan L; Mu L; Liu J; Feng F; Yang H; Zhao H; Schulz WL; Krumholz HM; Pan X; Li J;
    JAMA Netw Open; 2021 Sep; 4(9):e2127573. PubMed ID: 34586366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and types of persistent dyslipidemia in patients treated with statins.
    Reiner Ž; Tedeschi-Reiner E
    Croat Med J; 2013 Aug; 54(4):339-45. PubMed ID: 23986274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid-Lowering Therapy and Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement in High-Cardiovascular-Risk Patients in Fuzhou, China.
    Wang X; He Y; Wang T; Li C; Ma Z; Zhang H; Ma H; Zhao H
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):307-315. PubMed ID: 31918567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obesity, ultrasound indexes of fat depots and lipid goal attainment in patients with high and very high cardiovascular risk: A novel approach towards better risk reduction.
    Haberka M; Okopień B; Gąsior Z
    Nutr Metab Cardiovasc Dis; 2016 Feb; 26(2):123-33. PubMed ID: 26830392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).
    Devroey D; Radermecker RP; Van der Schueren BJ; Torbeyns B; Jaken RJ
    Int J Clin Pract; 2014 Feb; 68(2):180-7. PubMed ID: 24308644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency and predictors of cholesterol target attainment in patients with stable coronary heart disease in Belgium: results from the Dyslipidemia International Study II (DYSIS II
    Hermans MP; Gevaert S; Descamps O; Missault L; Gillot B; De Keyzer D; Lautsch D; Brudi P; Ambegaonkar B; Vyas A; Horack M; Gitt A
    Acta Clin Belg; 2019 Dec; 74(6):399-404. PubMed ID: 30355016
    [No Abstract]   [Full Text] [Related]  

  • 35. Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.
    Gitt AK; Lautsch D; Ferrieres J; Kastelein J; Drexel H; Horack M; Brudi P; Vanneste B; Bramlage P; Chazelle F; Sazonov V; Ambegaonkar B
    Atherosclerosis; 2016 Dec; 255():200-209. PubMed ID: 27667299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.
    Waters DD; Brotons C; Chiang CW; Ferrières J; Foody J; Jukema JW; Santos RD; Verdejo J; Messig M; McPherson R; Seung KB; Tarasenko L;
    Circulation; 2009 Jul; 120(1):28-34. PubMed ID: 19546386
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: the ICP-bypass study].
    González-Juanatey JR; Cordero A; Vitale GC; González-Timón B; Mazón P; Bertomeu V
    Rev Esp Cardiol; 2011 Oct; 64(10):862-8. PubMed ID: 21835533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.
    Vallejo-Vaz AJ; Fayyad R; Boekholdt SM; Hovingh GK; Kastelein JJ; Melamed S; Barter P; Waters DD; Ray KK
    Circulation; 2018 Aug; 138(8):770-781. PubMed ID: 29618599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial.
    Ballantyne CM; Raichlen JS; Cain VA
    J Am Coll Cardiol; 2008 Aug; 52(8):626-32. PubMed ID: 18702965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of dyslipidemia and goal attainment after initiating lipid-modifying therapy: a Thai multicenter study.
    Khovidhunkit W; Silaruks S; Chaithiraphan V; Ongphiphadhanakul B; Sritara P; Nimitphong H; Benjanuwattra T; Ambegaonkar BM
    Angiology; 2012 Oct; 63(7):528-34. PubMed ID: 22222187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.